Rising prices of targeted oral anticancer medications and associated financial burden on medicare beneficiaries

Journal of Clinical Oncology

Volumn 35, Issue 22, 2017, Pages

  Shih, Ya Chen Tina ^a   Xu, Ying ^a   Liu, Lei ^b   Smieliauskas, Fabrice ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BOSUTINIB; CRIZOTINIB; DASATINIB; ENZALUTAMIDE; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; LENALIDOMIDE; NILOTINIB; PAZOPANIB; REGORAFENIB; SORAFENIB; SUNITINIB; THALIDOMIDE; VANDETANIB; VEMURAFENIB; VISMODEGIB; VORINOSTAT;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; COHORT ANALYSIS; CONSUMER; CONTROLLED STUDY; DRUG COST; FEMALE; FINANCIAL DEFICIT; HEALTH CARE; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICARE; MULTICENTER STUDY; MYELOMA; PRESCRIPTION; PRIORITY JOURNAL; TARGETED ORAL ANTICANCER MEDICATION; COMMERCIAL PHENOMENA; COST OF ILLNESS; ECONOMICS; FEE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMMERCE; COST OF ILLNESS; FEMALE; HUMANS; MALE; MEDICARE PART D; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRESCRIPTION FEES; UNITED STATES;

EID: 85026779537     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.72.3742     Document Type: Article

References (46)

1. Sledge GW Jr: What is targeted therapy? J Clin Oncol 23:1614-1615, 2005
2. Aggarwal S: Targeted cancer therapies. Nat Rev Drug Discov 9:427-428, 2010
3. Kircher SM, Meeker CR, Nimeiri H, et al: The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications? Value Health 19:88-98, 2016
4. Geynisman DM, Wickersham KE: Adherence to targeted oral anticancer medications. Discov Med 15:231-241, 2013
5. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121:4439-4442, 2013
6. Newcomer LN: Myths and realities in cancer care: Another point of view. Health Aff (Millwood) 33: 1805-1807, 2014
7. Shih YC, Smieliauskas F, Geynisman DM, et al: Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol 33:2190-2196, 2015
8. Bennette CS, Richards C, Sullivan SD, et al: Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff (Millwood) 35:805-812, 2016
9. Dusetzina SB: Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014. JAMA Oncol 2: 960-961, 2016
10. Zafar SY, Abernethy AP: Financial toxicity, part I: A new name for a growing problem. Oncology (Williston Park) 27:80-81, 149, 2013
11. de Souza JA, Yap BJ, Hlubocky FJ, et al: The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer 120: 3245-3253, 2014
12. Altice CK, Banegas MP, Tucker-Seeley RD, et al: Financial hardships experienced by cancer survivors: A systematic review. J Natl Cancer Inst 109:109, 2016
13. Ramsey S, Blough D, Kirchhoff A, et al: Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32:1143-1152, 2013
14. Jagsi R, Pottow JA, Griffith KA, et al: Long-term financial burden of breast cancer: Experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 32: 1269-1276, 2014
15. Chino F, Peppercorn J, Taylor DH Jr, et al: Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist 19:414-420,2014
16. Regenbogen SE, Veenstra CM, Hawley ST, et al: The personal financial burden of complications after colorectal cancer surgery. Cancer 120:3074-3081, 2014
17. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011
18. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
19. Ramsey SD, Bansal A, Fedorenko CR, et al: Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34:980-986, 2016
20. EMD Serono: EMD Serono Specialty Digest, (ed 12). 2016
21. Report to the Congress: Medicare Payment Policy—March 2016. Medicare Payment Advisory Commission. http://www.medpac.gov/docs/default-source/reports/march-2016-report-to-the-congress-medicare-payment-policy.pdf
22. Report to the Congress: Medicare Payment Policy—March 2013. Medicare Payment Advisory Commission. http://www.medpac.gov/docs/default-source/reports/mar13_entirereport.pdf? sfvrsn=0
23. Report to the Congress—March 2017: Chapter 14, Status report on the Medicare prescription drug program (Part D). Medicare Payment Advisory Commission. http://www.medpac.gov/docs/defaultsource/reports/mar17_medpac_ch14.pdf?sfvrsn=0
24. Dusetzina SB, Keating NL: Mind the gap: Why closing the doughnut hole is insufficient for increasing Medicare beneficiary access to oral chemotherapy. J Clin Oncol 34:375-380, 2016
25. National Cancer Institute: Targeted cancer therapies, https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet
26. Bureau of Labor Statistics: CPI databases. https://www.bls.gov/cpi/data.htm
27. Centers for Medicare & Medicaid Services: 2015 Medicare Drug Spending Data. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/2015MedicareData.html
28. Trish E, Joyce G, Goldman DP: Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11. Health Aff (Millwood) 33:2018-2024, 2014
29. Ubel PA, Bach PB: Copay assistance for expensive drugs: A helping hand that raises costs. Ann Intern Med 165:878-879, 2016
30. Dafny LS, Ody CJ, Schmitt MA: Undermining value-based purchasing: Lessons from the pharmaceutical industry. N Engl J Med 375:2013-2015, 2016
31. Berndt ER, McGuire T, Newhouse JP: A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets. Forum for Health Economics & Policy 14:10, 2011
32. Hoadley J, Neuman T, Cubanski J: Health Affairs Blog: The cost of a cure: Revisiting Medicare Part D and hepatitis C drugs. http://kff.org/medicare/perspective/health-affairs-blog-the-cost-of-a-cure-revisiting-medicare-part-d-and-hepatitis-c-drugs/
33. QuintilesIMS: Global oncology trend report: A review of 2015 and outlook to 2020. http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/global-oncology-trend-report-a-review-of-2015-and-outlook-to-2020
34. Office of Inspector General: Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs. Washington, DC, Office of Inspector General, U.S. Department of Health and Human Services, 2014
35. Kantarjian H, Rajkumar SV: Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc 90:500-504, 2015
36. Ramsey SD, Lyman GH, Bangs R: Addressing skyrocketing cancer drug prices comes with tradeoffs: Pick your poison. JAMA Oncol 2:425-426, 2016
37. Kesselheim AS, Avorn J, Sarpatwari A: The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA 316: 858-871, 2016
38. Conti RM, Rosenthal MB: Pharmaceutical policy reform–balancing affordability with incentives for innovation. N Engl J Med 374:703-706, 2016
39. Zafar SY: Financial toxicity of cancer care: It’s time to intervene. J Natl Cancer Inst 108:108, 2015
40. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, NCCN Evidence Blocks: chronic myeloid leukemia version 2.2017
41. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, NCCN Evidence Blocks: kidney cancer Version 2.2017
42. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, NCCN Evidence Blocks: melanoma version 1.2017
43. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, NCCN Evidence Blocks: non-small cell lung cancer version 3.2017
44. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, NCCN Evidence Blocks: Acute lymphoblastic leukemia version 2.2016
45. Henrikson NB, Shankaran V: Improving price transparency in cancer care. J Oncol Pract 12:44-47, 2016
46. Herman B: Doctors, insurers flock to Medicare’s cancer payment demo despite questions. Modern Healthcare, June 29, 2016